Administration of Nrf-2-Modified Hair-Follicle MSCs Ameliorates DSS-Induced Ulcerative Colitis in Rats.

Lin Zhou,Jing Liu,Yongchen Wang,Rui Jiang,Fengjuan Yan,Limin Cai,Esra K Peli Akkol

doi:10.1155/2021/9930187

Abstract

Ulcerative colitis (UC) is a common chronic nonspecific intestinal inflammation of unknown etiology associated with a low cure rate and a high relapse rate. Hair follicle mesenchymal stem cells (HF-MSCs) are a class of pluripotent stem cells that have differentiation potential and strong proliferation ability. Nuclear factor red system related factor (Nrf-2) is a key factor in the oxidative stress response. Dextran sulfate sodium- (DSS-) induced rat UC models closely mimic human UC in terms of symptoms and histological changes. Animals were divided into five groups, including a healthy group and UC model rats treated with normal saline, Nrf-2, HF-MSCs, or Nrf-2-expressing HF-MSC group. Based on the expression of intestinal stem cells, inflammatory factors, anti-inflammatory factors, and disease activity index scores, Nrf-2-expressing HF-MSCs had the most obvious therapeutic effect under the same treatment regimen. This study provided a new potential clinical treatment option for ulcerative colitis.

Highlights

Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease which involves the colon and rectum as well as the ileum
In vitro-cultured Hair follicle mesenchymal stem cells (HF-Mesenchymal stem cells (MSCs)) isolated from male standard deviation (SD) rats were small in size, with a large nuclear/plasma ratio
Maintenance of the HF-MSC antigen phenotype was assessed by fluorescence-activated cell sorting (FACS)

Summary

Introduction

Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease which involves the colon and rectum as well as the ileum. The main clinical symptoms of the disease are enteritis, diarrhea, and intestinal bleeding, and the disease can be debilitating. The etiology of UC remains unclear, but it is generally believed to be related to genetic susceptibility, microbial infection, and environmental invasion [4]. Various drugs, such as tacrolimus, corticosteroids, and azathioprine are used to treat UC. These medications can alleviate UC symptoms; the adverse effects limit their therapeutic use [5,6,7]. New treatment options are warranted to improve the clinical management of UC patients

Methods

Results

Conclusion